Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Roche,Vemurafenib and cobimetinib,"Melanoma, stage III/IV with BRAF V600 mutation",Vemurafenib and cobimetinib,Only if cost neutral or cost saving,Hospital,Oncology Agents and Immunosuppressants
